eligibility_summary
Eligible: biopsy-confirmed primary MN or MCD/FSGS, nephrotic syndrome (protein >3.5 g/d, albumin <30 g/L) requiring immunosuppression, eGFR ≥60, consent. Exclude: prior rituximab, active infections (bacterial/fungal/TB/viral), secondary MN/MCD/FSGS (e.g., hepatitis, SLE, drugs, malignancy, genetic/diabetic), NYHA III–IV heart failure, uncontrolled HTN >180/110, pregnant/lactating, HIV/HBV/HCV, severe systemic/neurologic disease, other trials, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
A multicenter, prospective real‑world observational study evaluating frontline rituximab in primary glomerulonephritis with two cohorts: membranous nephropathy (MN) and minimal change disease/focal segmental glomerulosclerosis (MCD/FSGS). Drug/intervention: rituximab—chimeric anti‑CD20 IgG1 monoclonal antibody—depletes CD20+ B cells. Mechanism: reduces autoantibody production (e.g., anti‑PLA2R in MN), antigen presentation, and pro‑inflammatory cytokines, decreasing immune‑complex formation and complement activation, may also help stabilize podocyte function in nephrotic syndromes. Primary targets: B lymphocytes (CD20). Key pathways: CD20/BCR signaling, autoantibody‑mediated and complement pathways.